BCM
VIR icon

Boxer Capital Management’s Vir Biotechnology VIR Stock Holding History

Boxer Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Hold
1,866,000
– – 1.43% 16
2026
Q1 		$16.7M Buy
1,866,000
+1,241,000
+199% +$9.89M 2.2% 12
2025
Q4 		$3.77M Buy
+625,000
New +$3.72M 0.82% 31

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Boxer Capital Management's VIR Position: Q2 2026 in Review

Boxer Capital Management held its Vir Biotechnology (VIR) position steady in Q2 2026 at 1,866,000 shares worth $19M. The position accounts for 1.43% of the portfolio, ranked #16.

Boxer Capital Management first reported a position in VIR in Q4 2025 and has held it in 3 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Boxer Capital Management held 1,866,000 shares of Vir Biotechnology worth $19M as of Q2 2026.
  • Boxer Capital Management left its Vir Biotechnology share count unchanged in Q2 2026.
  • Vir Biotechnology made up 1.43% of Boxer Capital Management's portfolio in Q2 2026, its #16 holding.
  • Boxer Capital Management first reported a position in Vir Biotechnology in Q4 2025 and has held it in 3 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.